OwlTail

Cover image of Benjamin Levy

Benjamin Levy

13 Podcast Episodes

Latest 1 May 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Lung Cancer Special Nursing Edition Part 1 | Drs Benjamin Levy and Stephen Liu

Research To Practice | Oncology Videos

This program includes faculty lectures by Drs Benjamin Levy of Johns Hopkins Sidney Kimmel Cancer Center and Stephen Liu of Georgetown University on immune checkpoint inhibitors after chemotherapy with radiation therapy for Stage III NSCLC and toxicity reported in the PACIFIC trial. Access NCPD information and select publications here.

1hr

13 Jan 2021

Episode artwork

Lung Cancer | Benjamin Levy, MD

Research To Practice | Oncology Videos

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 6: Management of metastatic NSCLC in special populations — Dr Levy. CME information and select publications

18mins

21 Sep 2020

Similar People

Episode artwork

Dr Benjamin Levy on the Management of Lung Cancer in the COVID-19 Era

Oncology Today with Dr Neil Love

Dr Benjamin Levy from Johns Hopkins comments on changes to the surgical and targeted treatment of lung cancer during COVID-19 and challenges in the management of immune-related adverse events with immune checkpoint inhibitors. RTP Lung Cancer Summit Presentations Additional Resources Banna G et al. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open 2020;5(2). Abstract Kumar S et al. Alternative multidisciplinary management options for locally advanced non-small cell lung cancer during the COVID-19 global pandemic. J Thorac Oncol 2020;[Online ahead of print]. Abstract Thoracic Surgery Outcomes Research Network, Inc. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Ann Thorac Surg 2020;[Online ahead of print]. Abstract

19mins

19 May 2020

Episode artwork

Murray's Cabaret Club, discovering Soho's secret by Benjamin Levy with Josephine Pembroke MAN WEEK on Radio Gorgeous

Radio Gorgeous

In 1960 there were over 200 strip clubs, clip joints and peep shows in Soho. But there was a classy, glamourous establishment which surpassed all others and that was Murray’s Cabaret Club in Beak Street, London W1. Murray’s Cabaret Club was taken over in 1933 by Percival Murray, it was famous for its gorgeous showgirls and dancers who wore hand-made sumptuous costumes by leading costume designers. Today I welcome onto Man Week on Radio Gorgeous, Benjamin Levy, who has worked at the V&A and is writing a book about eight, bohemian, female artists models.  But, in this podcast we are talk about his book: Murray's Cabaret Club about the club's history and costumes but most importantly the dancers and showgirls who worked at the club. Murray's cabaret club by Benjamin Levy is published by The History Press https://www.thehistorypress.co.uk/publication/murrays-cabaret-club/9780750991322/#RadioGorgeous #ManWeek #Cabaret

41mins

2 Dec 2019

Most Popular

Episode artwork

Benjamin Levy, MD - Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/WED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–small cell lung cancer (NSCLC) is one of the tumor types where the novel class of cancer immunotherapies—the immune checkpoint inhibitors—has had the biggest impact and certainly become a major component of the treatment arsenal in the advanced disease setting. While the approval and availability of an increasing number and variety of immunotherapeutic agents and combinatorial options has been welcomed by clinicians and patients alike, clinical decision-making has also become quite complicated. How to identify the right candidates for immunotherapy? What biomarkers should be tested to guide candidate selection? And which agent or combination to use for individual patients? All these questions and more are explored in this engaging and entertaining educational session based on a live symposium held adjunct to the 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019). Modeled after the format of a late-night talk show, this activity merges focused talks on defined topics with personal story-telling, candid interviews, and interactive debates/discussions among top experts. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies and combinations in the frontline setting and beyond in advanced/metastatic NSCLC, Assess the role of predictive biomarkers (PD-L1, TMB) and other tumor-, patient-, and treatment-related factors that should be taken into consideration as part of individualized treatment planning and selection for patients with NSCLC, Describe key new research directions and clinical trials with immunotherapies aiming to refine, expand, and maximize their use throughout the lung cancer continuum, including novel immune targets or combinations and biomarkers in advanced settings, as well as potentially curative approaches in earlier stages of NSCLC, Implement individualized, evidence-based, patient-centric treatment plans involving immunotherapies and/or combinations for patients with NSCLC.

1hr 25mins

9 Aug 2019

Episode artwork

Benjamin Levy, MD - Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/WED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–small cell lung cancer (NSCLC) is one of the tumor types where the novel class of cancer immunotherapies—the immune checkpoint inhibitors—has had the biggest impact and certainly become a major component of the treatment arsenal in the advanced disease setting. While the approval and availability of an increasing number and variety of immunotherapeutic agents and combinatorial options has been welcomed by clinicians and patients alike, clinical decision-making has also become quite complicated. How to identify the right candidates for immunotherapy? What biomarkers should be tested to guide candidate selection? And which agent or combination to use for individual patients? All these questions and more are explored in this engaging and entertaining educational session based on a live symposium held adjunct to the 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019). Modeled after the format of a late-night talk show, this activity merges focused talks on defined topics with personal story-telling, candid interviews, and interactive debates/discussions among top experts. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies and combinations in the frontline setting and beyond in advanced/metastatic NSCLC, Assess the role of predictive biomarkers (PD-L1, TMB) and other tumor-, patient-, and treatment-related factors that should be taken into consideration as part of individualized treatment planning and selection for patients with NSCLC, Describe key new research directions and clinical trials with immunotherapies aiming to refine, expand, and maximize their use throughout the lung cancer continuum, including novel immune targets or combinations and biomarkers in advanced settings, as well as potentially curative approaches in earlier stages of NSCLC, Implement individualized, evidence-based, patient-centric treatment plans involving immunotherapies and/or combinations for patients with NSCLC.

1hr 25mins

9 Aug 2019

Episode artwork

Benjamin Levy, MD - Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/WED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–small cell lung cancer (NSCLC) is one of the tumor types where the novel class of cancer immunotherapies—the immune checkpoint inhibitors—has had the biggest impact and certainly become a major component of the treatment arsenal in the advanced disease setting. While the approval and availability of an increasing number and variety of immunotherapeutic agents and combinatorial options has been welcomed by clinicians and patients alike, clinical decision-making has also become quite complicated. How to identify the right candidates for immunotherapy? What biomarkers should be tested to guide candidate selection? And which agent or combination to use for individual patients? All these questions and more are explored in this engaging and entertaining educational session based on a live symposium held adjunct to the 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019). Modeled after the format of a late-night talk show, this activity merges focused talks on defined topics with personal story-telling, candid interviews, and interactive debates/discussions among top experts. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies and combinations in the frontline setting and beyond in advanced/metastatic NSCLC, Assess the role of predictive biomarkers (PD-L1, TMB) and other tumor-, patient-, and treatment-related factors that should be taken into consideration as part of individualized treatment planning and selection for patients with NSCLC, Describe key new research directions and clinical trials with immunotherapies aiming to refine, expand, and maximize their use throughout the lung cancer continuum, including novel immune targets or combinations and biomarkers in advanced settings, as well as potentially curative approaches in earlier stages of NSCLC, Implement individualized, evidence-based, patient-centric treatment plans involving immunotherapies and/or combinations for patients with NSCLC.

1hr 25mins

9 Aug 2019

Episode artwork

VPL119 | Interview with Benjamin Levy, MD and Raymond Lobins, DO

Lung Cancer Update

A case-based discussion on the management of metastatic non-small cell lung cancer. Interview with Benjamin Levy, MD and Raymond Lobins, DO conducted by Neil Love, MD. Produced by Research To Practice.

1hr 14mins

30 Jul 2019

Episode artwork

Benjamin Levy, MD - Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC: Evolving Science, New Standards of Care, and Implications for Multidisciplinary Management

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/CXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The best practices for management of patients with EGFR-mutant NSCLC continue to evolve as a result of advances in molecular testing and targeted treatment. Understanding what, when, and how to test, as well as how to select therapy, throughout the continuum of advanced NSCLC is paramount. In this activity, based on a recent live symposium held in San Diego, California, experts in EGFR-mutant NSCLC provide a concise but comprehensive overview of all the recent key evidence and new research directions and provide practical guidance for how to navigate clinical decisions in EGFR-mutant NSCLC in different settings and patient populations. Upon completion of this activity, participants will be able to: Discuss the latest recommendations for tissue- and blood-based molecular testing to evaluate EGFR mutation status in patients with advanced/metastatic NSCLC, Assess the characteristics, safety/efficacy profiles, and indications of the different EGFR inhibitors available for the treatment of EGFR-positive NSCLC in different settings and patient populations, including those with brain or leptomeningeal metastases, Evaluate the current evidence related to the mechanisms of acquired resistance to the various EGFR TKIs used in the first line and subsequent therapy of advanced EGFR-mutant NSCLC, Implement best practices related to molecular testing for EGFR mutations through the continuum of advanced NSCLC, and interpret results to guide treatment selection, Implement evidence-based, individualized treatment plans for patients with EGFR-mutant NSCLC.

1hr 4mins

3 May 2019

Episode artwork

Benjamin Levy, MD - Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC: Evolving Science, New Standards of Care, and Implications for Multidisciplinary Management

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/CXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The best practices for management of patients with EGFR-mutant NSCLC continue to evolve as a result of advances in molecular testing and targeted treatment. Understanding what, when, and how to test, as well as how to select therapy, throughout the continuum of advanced NSCLC is paramount. In this activity, based on a recent live symposium held in San Diego, California, experts in EGFR-mutant NSCLC provide a concise but comprehensive overview of all the recent key evidence and new research directions and provide practical guidance for how to navigate clinical decisions in EGFR-mutant NSCLC in different settings and patient populations. Upon completion of this activity, participants will be able to: Discuss the latest recommendations for tissue- and blood-based molecular testing to evaluate EGFR mutation status in patients with advanced/metastatic NSCLC, Assess the characteristics, safety/efficacy profiles, and indications of the different EGFR inhibitors available for the treatment of EGFR-positive NSCLC in different settings and patient populations, including those with brain or leptomeningeal metastases, Evaluate the current evidence related to the mechanisms of acquired resistance to the various EGFR TKIs used in the first line and subsequent therapy of advanced EGFR-mutant NSCLC, Implement best practices related to molecular testing for EGFR mutations through the continuum of advanced NSCLC, and interpret results to guide treatment selection, Implement evidence-based, individualized treatment plans for patients with EGFR-mutant NSCLC.

1hr 4mins

3 May 2019

Loading